Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.34 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.30 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14716694 | 0.89 | SIRT2 (0.33) | SIRT2SIRT1 | |
| SCHEMBL12480762 | 0.84 | SIRT2 (0.36) | SIRT2SIRT1PKN1PKN2 | |
| SCHEMBL14716300 | 0.84 | HRH1 (0.46) | — | |
| SCHEMBL13833888 | 0.83 | SIRT2 (0.37) | SIRT2SIRT1PKN1PKN2 | |
| SCHEMBL14719655 | 0.78 | — | — | |
| SCHEMBL14716251 | 0.74 | HRH1 (0.41) | SIRT2SIRT1 | |
| SCHEMBL13834536 | 0.72 | SIGMAR1 (0.35) | SIRT2SIRT1 | |
| SCHEMBL13833891 | 0.71 | SIRT2 (0.35) | SIRT2SIRT1 | |
| SCHEMBL13834062 | 0.70 | HRH1 (0.61) | — | |
| SCHEMBL16638430 | 0.69 | KMT2A (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2015-09-24 | — | — | US | disclosed |
| US-9006263-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8815843-B2 | Compounds and methods of treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8791132-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20140088086-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20130190294-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | SIRT2 1447/4885SIRT1 2145/4885PKN1 1200/4885 |
| US-20130190294-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | SIRT2 729/4885SIRT1 2207/4885PKN1 2266/4885 |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | SIRT2 1447/4885SIRT1 2145/4885PKN1 1200/4885 |
| US-20140088086-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | SIRT2 1447/4885SIRT1 2145/4885PKN1 1200/4885 |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | SIRT2 738/4885SIRT1 2196/4885PKN1 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.